Mallinckrodt Pharmaceuticals Competitors and Similar CompaniesClear all

Mallinckrodt Pharmaceuticals's competitors and similar companies include Opsy, Indaptus Therapeutics, OnCusp Therapeutics and Dendreon.

	Mallinckrodt Pharmaceuticals Mallinckrodt is a business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies.	Opsy Opsy Holding (formerly WntResearch) is a biotech company that develops therapies for preventing cancer spread.	Indaptus Therapeutics Indaptus Therapeutics. is a biopharmaceutical company that specializes in cancer and other infectious disease treatment solutions.	OnCusp Therapeutics OnCusp Therapeutics is a biopharmaceutical company that specializes in cancer treatment solutions.	Dendreon Dendreon Pharmaceuticals (formerly known as Activated Cell Therapy) is a biopharmaceutical company that engages in the development of immunotherapy.
Founding Date	Founding Date 1867	Founding Date 2007	Founding Date 2021	Founding Date 2021	Founding Date 1992
Type	Type Private	Type Public	Type Public	Type Private	Type Subsidiary
Tags	Tags Healthcare oncology pharma therapy	Tags Healthcare oncology pharma therapy	Tags Healthcare oncology pharma therapy	Tags Healthcare oncology pharma therapy	Tags Healthcare biotech oncology pharma therapy
Locations	Locations Dublin 15, IE HQ Staines, GB Hazelwood, US Webster Groves, US	Locations Gothenburg, SE HQ Lund, SE	Locations HQ	Locations New York, US HQ Shanghai, CN Shanghai, CN	Locations Seal Beach, US HQ Seattle, US Union City, US Tampa, US
Employees	Employees 3,373	Employees 2	Employees N/A	Employees 2519% increase	Employees 6131% decrease
Valuation ($)	Valuation ($) N/A	Valuation ($) 721.5 k	Valuation ($) 12.6 m	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) $1b (FY, 2022)	Revenue (est.) kr6.7m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods $643.5m (FY, 2022)	Cost of goods kr1.3m (FY, 2025)	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit $396.2m (FY, 2022)	Gross profit kr5.4m (FY, 2025)	Gross profit N/A	Gross profit N/A	Gross profit N/A
Net income	Net income ($598.3m) (FY, 2022)	Net income (kr17.2m) (FY, 2025)	Net income N/A	Net income N/A	Net income N/A